12 labourers injured in landslide at project site in Uttarakhand's Chamoli
District Magistrate Sandeep Tiwari said that there were around 300 labourers at work at the project site when the landslide occurred.
They ran for life as a rock began to roll down from a hill. Eight of them sustained minor injuries, while four were seriously injured, he added.
The district magistrate said that all injured labourers were admitted to Vivekanand Hospital in Pipalkoti.
One of them has got a fracture in the leg, while another labourer on whom a spinal MRI needs to be done is being taken in an ambulance to a hospital in Srinagar in Pauri district, he added.
Tiwari said the MRI report will reveal the severity of his injury.
The district magistrate further said that there were around 70 labourers present on the spot where the landslide occurred, adding the work has been suspended for the time being at the project site.
"THDC has been asked to resume work at the site only after ensuring the safety of those at work," he said.
The State Disaster Response Force (SDRF), police and health department personnel rushed to the spot after being informed about the landslide.
The THDC is building a barrage to stop the water of Alaknanda river from Helang near Joshimath. The water of Alaknanda river from this barrage will be brought to Pipalkoti through a tunnel where electricity is to be generated through turbines.
Earlier in 2021, the barrage side was damaged due to flood in Alaknanda river.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
28 minutes ago
- Time of India
Bengaluru's deep-tech startup proposes 'quantum' leap in cancer care
Bengaluru: A Bengaluru-based bootstrapped deep-tech startup is leveraging quantum technology to detect cellular damage even before the symptoms appear, in just hours, possibly changing the game for cancer care . One among the 20-odd exhibitors at the recently concluded Quantum India Bengaluru Summit, Quantum Biosciences Private Limited's "predictive tech" uses quantum biosensor to detect unique 'magnetic fingerprints' of oxidative stress in cells, allowing detection of tissue injury. When somebody close to him was diagnosed with cancer and had to undergo radiation therapy, Ravi Puvvala, Managing Director of Quantum Biosciences, who was earlier developing sensors for automotive industry, said he started exploring the possibility of using sensors to predict radiation-induced cardiotoxicity before irreversible damage. "Radiation therapy is essential for treating cancer. However, it kills not only the cancerous cells, but also the good ones. This leads to long-term complications such as fatigue, cognitive decline, organ dysfunction and secondary cancers. It also potentially induces a heart disease or fibrosis." Puvvala told PTI. Existing diagnostic tools, such as MRI, PET scans and blood biomarkers only detect harm after significant damage has already occurred, said Puvvala. "So, I wanted to use my experience in building sensors, and, you know, explore technology, understand how to optimise this particular problem," added Puvvala. He has been building technologies for the last 15 years, Puvvala said. Things took a quantum leap when he partnered with the Netherlands-based QT Sense, led by another Banglorean, Deepak Veeregowda. QT Sense was formed to take forward the 15 years of academic research done in this area at the University of Groningen. QT Sense's Quantum Nuova is a platform technology built for detecting quantum-level phenomena like subcellular free radicals and magnetic biomarkers. "For the last two years, we have been researching various potential technologies for early-stage diagnostics. We looked at classical sensors and quantum sensors , and we started quantum biosensors to leverage the potential of quantum sensors," said Puvvala. Puvvala said while quantum biosensors can tell us that there exists a certain amount of stress at the subcellular level, the next step would be to understand how to read, classify and relate them to a potential biomarker. "Further research is needed on how to map the cellular stress to a potential biomarker, only then we can say, okay, we made the prognosis," added Puvvala. At the first edition of the Quantum India Bengaluru Summit, Puvvala reached out to researchers and other key stakeholders - including the government of Karnataka, academic institutions like Indian Institute of Science, acute care clinicians and hospitals -- exploring this idea. "To build this technology, we need a whole village. We need the engineering team, we need the medical team, and we need, you know, people like us, who can put all this together," said Puvvala. According to him, they still need to do a lot of validation with respect to the sub cellular detection. "For the first time we're able to actually go inside the cell and measure all kinds of things. But now we need to be able to make sense of what these measurements mean through clinical tests. So, we need to conduct tests, and we need to be able to come up with a diagnostic mechanism," said Puvvala. To this end, Puvvala said they would be spending the next two years working with various hospitals, both in India and abroad. "We want to partner with cancer centres particularly, so we could get the necessary data," said Puvvala. Quantum Biosciences is at present incubating its foundational research capabilities at Centre for Cellular and Molecular Platforms (C-CAMP), an initiative of Department of Biotechnology, Ministry of Science and Technology, Government of India and at Centre for Nano Science and Engineering (CeNSE) in Indian Institute of Science (IISc), Bengaluru, he added. "We are also talking to other ecosystem leaders and state-level innovation programs to co-develop a shared infrastructure that bridges deep-science research with clinical applications," said Puvvala. When they go past the "very base-level mechanism", the technology, said Puvvala, would benefit not only oncology, but also nephrology, cardiovascular and neurodegenerative diseases. It could even help India's most basic struggle in providing health care, he added. "One of the things I've heard at the conference is that most hospitals are overcrowded because the primary health care and the critical health care have been combined into one. The quantum biosensor could, you know, reduce the primary health care overload, by precisely identifying those cases that need critical care at a considerably lesser time," said Puvvala. PTI
Time of India
15 hours ago
- Time of India
‘Foul play' alleged over solo BMC MRI tenders
Mumbai: In several tenders over the last couple of years, only one MRI manufacturer bid to supply machines for all four BMC-run medical college hospitals. Insiders now allege that the tender's terms were manipulated to favour this manufacturer, effectively blocking other companies from competing. A technical team comprising heads of radiology departments is responsible for deciding the required specifications. "These specifications heavily favour Siemens in the bidding process over a number of other companies. At this point, there needs to be a departmental enquiry into it after many years of delay, which impacted patient care," said a senior radiologist at one of the BMC hospitals. For instance, the tender specifies certain machine requirements, like 64 channels (which receive signals from the body), a gradient strength of 62 to 200 millitesla per meter (which affects image resolution and scan speed), and a 3-tesla rating. These conditions exclude several other companies like Philips, which offers only 32 channels, and GE Healthcare, which does not feature high shimmering -- mentioned as a requirement in minutes of the health department's meeting -- but provides "auto shimmering" instead. You Can Also Check: Mumbai AQI | Weather in Mumbai | Bank Holidays in Mumbai | Public Holidays in Mumbai Moreover, the radiologist said that when another potential bidder, United Imaging, entered the picture, a new country-specific clause was introduced to disqualify it. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Breakthrough "Skinny Pill" Takes Australia By Storm Her Life & Health Learn More Undo The tender floated this time states: "Magnet should be manufactured in the USA, Europe, or Japan." United Imaging manufactures this component in China. A Siemens Healthineers spokesperson said, "The tender's technical committee has engaged in multiple rounds of discussions with all prospective bidders. It is important to note that the specifications outlined in the tender are not unique to Siemens Healthineers. In fact, such units with comparable specifications have been procured by several government institutions across India." DMC (CPD) Sandhya Nandedkar said, "We extended it eight times because there was only a single bidder. Earlier tenders were cancelled due to higher quoted rates. The committee has been insisting that these requirements are necessary." One of the top former BMC officials said an earlier tender was set aside due to the lack of multi-bidder specifications. "It was turning out to be a more expensive endeavour as well. If the experts specifically wanted that particular machine for technical reasons, they could have opted for proprietary procurement instead of going through the farce of a tender process," said the official. Dr Neelam Andrade, Director of BMC Hospitals, said, "It was conveyed to all the HoDs that the terms should be such that multiple bidders can participate. We do not know why other companies chose not to come forward." A radiology HoD from one of the hospitals said, "We want to buy a high-end MRI for our poor patients, and we design the specifications accordingly. It's not that we want to favour Siemens; it's not our fault that no one else bids." A representative from one of the companies that participated in BMC's recent pre-bid meeting said, "One can bid only if there's a chance of winning. If the terms and conditions make it clear we won't win, we don't invest in the fees and earnest money deposits." BMC's AMC (health) Vipin Sharma and DMC (health) Sharad Ughade did not respond to queries till press time. Get the latest lifestyle updates on Times of India, along with Friendship Day wishes , messages and quotes !
Time of India
a day ago
- Time of India
Bengaluru's deep-tech startup proposes 'quantum' leap in cancer care
A Bengaluru-based bootstrapped deep-tech startup is leveraging quantum technology to detect cellular damage even before the symptoms appear in just hours, possibly changing the game for cancer care One among the 20-odd exhibitors at the recently concluded Quantum India Bengaluru Summit, Quantum Biosciences Private Limited's "predictive tech" uses quantum biosensor to detect unique 'magnetic fingerprints' of oxidative stress in cells, allowing detection of tissue his wife was diagnosed with cancer and had to undergo radiation therapy, Ravi Puvvala, Managing Director of Quantum Biosciences, who was earlier developing sensors for automotive industry, said he started exploring the possibility of using sensors to predict radiation-induced cardiotoxicity before irreversible damage."Radiation therapy is essential for treating cancer. But it kills not only the cancerous cells, also the good ones. This leads to long-term complications such as fatigue, cognitive decline, organ dysfunction and secondary cancers. It also potentially induces a heart disease or fibrosis. I watched my wife suffer because of some of these side effects," Puvvala told diagnostic tools, such as MRI, PET scans and blood biomarkers only detect harm after significant damage has already occurred, said Puvvala."So, I wanted to use my experience in building sensors, and, you know, explore technology, understand how to optimise this particular problem," added has been building technologies for the last 15 years, Puvvala took a quantum leap when he partnered with the Netherlands-based QT Sense, led by another Indian, Deepak Veeragowda. QT Sense was formed to take forward the 15 years of academic research done in this area at the University of Sense's Quantum Nuova is a platform technology built for detecting quantum-level phenomena like subcellular free radicals and magnetic biomarkers."For the last two years, we have been researching various potential technologies for early stage diagnostics. We looked at classical sensors and quantum sensors , and we started quantum biosensors to leverage the potential of quantum sensors," said said while quantum biosensors can tell us that there exists a certain amount of stress at the subcellular level, the next step would be to understand how to read them."Further research is needed on how to map the cellular stress to a potential biomarker, only then we can say, okay, we made the prognosis," added the first edition of the Quantum India Bengaluru Summit, Puvvala reached out to researchers and other key stakeholders - including the government of Karnataka, academic institutions, acute care clinicians, pharmaceutical companies and hospitals -- exploring this idea."To build this technology, we need a whole village. We need the engineering team, we need the medical team, and we need, you know, people like us, who can put all this together," said to him, they still need to do a lot of validation with respect to the sub cellular detection."For the first time we're able to actually go inside the cell and measure all kinds of things. But now we need to be able to make sense of what these measurements mean through clinical tests. So we need to conduct tests, and we need to be able to come up with a diagnostic mechanism," said this end, Puvvala said they would be spending the next two years working with various hospitals, both in India and abroad."We want to partner with cancer centres particularly, so we could get the necessary data," said Biosciences is at present incubating its foundational research capabilities at Center for Cellular and Molecular Platforms (C-CAMP), an initiative of Department of Biotechnology, Ministry of Science and Technology, Government of India and at Center for Nano Science and Engineering (CeNSE) in Indian Institute of Science (IISc), Bengaluru, he added."We are also talking to other ecosystem leaders and state-level innovation programs to co-develop a shared infrastructure that bridges deep-science research with clinical applications," said they go past the "very base-level mechanism", the technology, said Puvvala, would benefit not only oncology, but also nephrology, cardiovascular and neurodegenerative could even help India's most basic struggle in providing health care, he added."One of the things I've heard at the conference is that most hospitals are overcrowded because the primary health care and the critical health care have been combined into one. The quantum biosensor could, you know, reduce the primary health care overload, by precisely identifying those cases that need critical care at a considerably lesser time," said Puvvala.
